Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine is under clinical development by CanSino Biologics and currently in Phase III for Neisseria meningitidis Infections. According to GlobalData, Phase III drugs for Neisseria meningitidis Infections have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine overview
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine) (Menhycia) is a sterile liquid vaccine. It is formulated as lyophilized injection solution for intramuscular route of administration. Menhycia is indicated for the prevention of epidemics caused by group A, C, Y and W135 Neisseria meningitidis and cerebrospinal meningitis.
It is under development for the prevention of Neisseria meningitidis infections and meningitis for people aged 7-59 years old and 4 to 6 year-old Population.
CanSino Biologics overview
CanSino Biologics. (CanSinoBIO) is a biopharmaceutical company that researches, develops, manufactures, and commercializes vaccine products for human use. The company offers pipeline products such as ConvideciaAir (Recombinant COVID-19 vaccine (adenovirus type 5 Vector) for Inhalation), Convidecia (recombinant novel coronavirus vaccine (adenovirus type 5 vector), Menphecia (group A and group C meningococcal conjugate vaccine (CRM197 vector), Menhycia (group ACYW135 meningococcal conjugate vaccine (CRM197 vector), and Ad5-EBOV. CanSinoBIO’s technology platform includes adenovirus-based viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA and LNP technology, and formulation and drug delivery technology. The company operates manufacturing offices in Mexico, China, Pakistan, and Malaysia. CanSino Biologics is headquartered in Tianjin, China.
For a complete picture of Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
